The spectrum of use of rituximab in chronic lymphocytic leukemia

References

• National Cancer InstituteSEER Cancer Statistics Review1975 —2007http://seer.cancer.gov/csr/1975_2007/Accessed 2010 Oct 30
   Google Scholar
• DighieroGHamblinTJChronic lymphocytic leukaemiaLancet20083711017102918358929
   PubMed Web of Science ®Google Scholar
• BinetJLAuquierADighieroGA new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysisCancer1981481982067237385
   PubMed Web of Science ®Google Scholar
• RaiKRSawitskyACronkiteEPClinical staging of chronic lymphocytic leukemiaBlood1975462192341139039
   PubMed Web of Science ®Google Scholar
• MontilloMHamblinTHallekMChronic lymphocytic leukemia: novel prognostic factors and their relevance for risk-adapted therapeutic strategiesHaematologica20059039139915749671
   PubMed Web of Science ®Google Scholar
• MontserratEClassical and new prognostic factors in chronic lymphocytic leukemia: where to now?Hematol J200237911960388
   PubMedGoogle Scholar
• DohnerHStilgenbauerSBennerAGenomic aberrations and survival in chronic lymphocytic leukemiaN Engl J Med20003431910191611136261
   PubMed Web of Science ®Google Scholar
• DamleRNWasilTFaisFIg V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemiaBlood1999941840184710477712
   PubMed Web of Science ®Google Scholar
• HamblinTDavisZGardinerAUnmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemiaBlood1999941848185410477713
   PubMed Web of Science ®Google Scholar
• CrespoMBoschFVillamorNZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemiaN Engl J Med20033481764177512724482
   PubMed Web of Science ®Google Scholar
• di GiovanniSValentiniGCarducciPBeta-2-microglobulin is a reliable tumor marker in chronic lymphocytic leukemiaActa Haematol1989811811852502891
   PubMed Web of Science ®Google Scholar
• CLL Trialists’ Collaborative GroupChemotherapeutic options in chronic lymphocytic leukemia: a meta-analysis of the randomized trials. CLL Trialists’ Collaborative GroupJ Natl Cancer Inst19999186186810340906
   PubMed Web of Science ®Google Scholar
• ChesonBDBennetJMGreverMNational Cancer Institutesponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatmentBlood199687499049978652811
   PubMed Web of Science ®Google Scholar
• HallekMChesonBDCatovskyDGuidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelinesBlood20081115446545618216293
   PubMed Web of Science ®Google Scholar
• KeatingMJO’BrienSKantariianLong-term follow-up of patients with chronic lymphocytic leukemia treated with fludarabine as a single agentBlood199381287828848499626
   PubMed Web of Science ®Google Scholar
• RaiKRPetersonBLAppelbaumFRFludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemiaN Engl J Med20003431750175711114313
   PubMed Web of Science ®Google Scholar
• JohnsonSSmithAGLofflerHMulticentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia. The French Cooperative Group on CLLLancet1996347143214388676625
   PubMed Web of Science ®Google Scholar
• LeporrierMChevretSCazinBRandomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patientsBlood2001982319232511588025
   PubMed Web of Science ®Google Scholar
• KeatingMJO’BrienSLernerSLong-term follow-up of patients with chronic lymphocytic leukemia (CLL) receiving fludarabine regimens as initial therapyBlood199892116511719694704
   PubMed Web of Science ®Google Scholar
• CatovskyDRichardsSMatutesEAssessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trialLancet200737023023917658394
   PubMed Web of Science ®Google Scholar
• BoschFFerrerALopez-GuillermoAFludarabine, cyclophosphamide and mitoxantrone in the treatment of resistant or relapsed chronic lymphocytic leukaemiaBr J Haematol200211997698412472576
   PubMed Web of Science ®Google Scholar
• SteurerMPallGRichardsSSingle-agent purine analogues for the treatment of chronic lymphocytic leukaemia: a systematic review and meta-analysisCancer Treat Rev20063237738916793209
   PubMed Web of Science ®Google Scholar
• KeatingMJCoutrèSRaiKManagement guidelines for use of alemtuzumab in B-cell chronic lymphocytic leukemiaClin Lymphoma2004422022715072613
   PubMedGoogle Scholar
• MontserratERituximab in chronic lymphocytic leukemiaSemin Oncol200330343912652463
   PubMed Web of Science ®Google Scholar
• AlasSEmmanouilidesCBonavidaBInhibition of interleukin 10 by rituximab results in down-regulation of bcl-2 and sensitization of B-cell non-Hodgkin’s lymphoma to apoptosisClin Cancer Res2001770972311297268
   PubMed Web of Science ®Google Scholar
• di GaetanoNXiaoYErbaESynergism between fludarabine and rituximab revealed in a follicular lymphoma cell line resistant ot the cytotoxic activity of either drug aloneBr J Haematol200111480080911564066
   PubMed Web of Science ®Google Scholar
• TamCSO’BrienSWierdaWLong-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemiaBlood200811297598018411418
   PubMed Web of Science ®Google Scholar
• RobakTDmoszynskaASolal-CelignyPRituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemiaJ Clin Oncol2010281756176520194844
   PubMed Web of Science ®Google Scholar
• HallekMState-of-the-art treatment of chronic lymphocytic leukemiaHematology Am Soc Hematol Educ Program200944044920008230
   PubMed Web of Science ®Google Scholar
• KeatingMJO’BrienSAlbitarMEarly results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemiaJ Clin Oncol2005234079408815767648
   PubMed Web of Science ®Google Scholar
• HallekMFingerle-RowsonGFinkAMFirst-line treatment with fludarabine (f), cyclophosphamide (C), and rituximab (R) (FCR) improves overall survival (OS) in previously untreated patients (pts) with advanced chronic lymphocytic leukemia (CLL): results of a randomized phase III trial on behalf of an international group of investigators and the German CLL Study GroupBlood2009114Abstract 535
   Web of Science ®Google Scholar
• MoretonPKennedyBLucasGEradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survivalJ Clin Oncol2005232971297915738539
   PubMed Web of Science ®Google Scholar
• DregerPCorradiniPKimbyEIndications for allogeneic stem cell transplantation in chronic lymphocytic leukemia: the EBMT transplant consensusLeukemia200721121717109028
   PubMed Web of Science ®Google Scholar
• TobinaiKRituximab and other emerging antibodies as molecular target-based therapy of lymphomaInt J Clin Oncol2003821222312955576
   PubMedGoogle Scholar
• SmithMRRituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistanceOncogene2003227359736814576843
   PubMed Web of Science ®Google Scholar
• GinaldiLde MartinisMMatutesELevels of expression of CD19 and CD20 in chronic B cell leukaemiasJ Clin Pathol1998513643699708202
   PubMed Web of Science ®Google Scholar
• GlennieMJFrenchRRCraggMSMechanisms of killing by anti-CD20 monoclonal antibodiesMol Immunol2007443823383717768100
   PubMed Web of Science ®Google Scholar
• CraggMSWalsheCAIvanoyAOThe biology of CD20 and its potential as a target for mAb therapyCurr Dir Autoimmun2005814017415564720
   PubMedGoogle Scholar
• DemidemALamTAlasSChimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugsCancer Biother Radiopharm19971217718610851464
   PubMed Web of Science ®Google Scholar
• ManchesOLuiGChaperotLIn vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomasBlood200310194995412393572
   PubMed Web of Science ®Google Scholar
• HarjunpaaAJunnikkalaSMeriSRituximab (anti-CD20) therapy of B-cell lymphomas: direct complement killing is superior to cellular effector mechanismsScand J Immunol20005163464110849376
   PubMed Web of Science ®Google Scholar
• CartronGDacheuxLSallesGTherapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa geneBlood20029975475811806974
   PubMed Web of Science ®Google Scholar
• FaragSSFlinnIWModaliRFc gamma RIIIa and Fc gamma RIIa polymorphisms do not predict response to rituximab in B-cell chronic lymphocytic leukemiaBlood20041031472147414563637
   PubMed Web of Science ®Google Scholar
• TreonSPMitsiadesCMitsiadesNTumor cell expression of CD59 is associated with resistance to CD20 serotherapy in patients with B-cell malignanciesJ Immunother200124263271
   PubMed Web of Science ®Google Scholar
• GolayJZaffaroniLVaccariTBiologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysisBlood2000953900390810845926
   PubMed Web of Science ®Google Scholar
• GolayJZaffaroniLVaccariTBiologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysisBlood2000953900390810845926
   PubMed Web of Science ®Google Scholar
• PedersenIMKitadaSSchimmerAThe triterpenoid CDDO induces apoptosis in refractory CLL B cellsBlood20021002965297212351409
   PubMed Web of Science ®Google Scholar
• SelenkoNMajdicOJagerUCross-priming of cytotoxic T cells promoted by apoptosis-inducing tumor cell reactive antibodies?J Clin Immunol20022212413012078853
   PubMed Web of Science ®Google Scholar
• SelenkoNMajdicODraxierSCD20 antibody (C2B8)-induced apoptosis of lymphoma cells promotes phagocytosis by dendritic cells and cross-priming of CD8+ cytotoxic T cellsLeukemia2001151619162611587221
   PubMed Web of Science ®Google Scholar
• MaloneyDGGrillo-LopezAJBodkinDJIDEC-C2B8: Results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin’s lymphomaJ Clin Oncol199715326632749336364
   PubMed Web of Science ®Google Scholar
• ForanJMRohatinerAZCunninghamDEuropean phase II study of Rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma, immunocytoma and small B-cell lymphocytic lymphomaJ Clin Oncol20001831732410637245
   PubMed Web of Science ®Google Scholar
• McLaughlinPGrillo-LopezAJLinkBKRituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment programJ Clin Oncol199816282528339704735
   PubMed Web of Science ®Google Scholar
• WinklerUJensenMManzkeOCytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (Rituximab, IDEC-C2B8)Blood1999942217222410498591
   PubMed Web of Science ®Google Scholar
• NguyenDTAmessJADoughtyHIDEC-C2B8 anti-CD20 (rituximab) immunotherapy in patients with low-grade non-Hodgkin’s lymphoma and lymphoproliferative disorders: Evaluation of response on 48 patientsEur J Haematol199962768210052709
   PubMed Web of Science ®Google Scholar
• HuhnDvon SchillingCWilhelmMRituximab therapy of patients with B-cell chronic lymphocytic leukemiaBlood2001981326133111520778
   PubMed Web of Science ®Google Scholar
• ItalaMGeislerCHKimbyEStandard-dose anti-CD20 antibody rituximab has efficacy in chronic lymphocytic leukaemia: results from a Nordic multicentre studyEur J Haematol20026912913412406005
   PubMed Web of Science ®Google Scholar
• O’BrienSMKantarjianHThomasDARituximab doseescalation trial in chronic lymphocytic leukemiaJ Clin Oncol2001192165217011304768
   PubMed Web of Science ®Google Scholar
• ByrdJCMurphyTHowardRSRituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicityJ Clin Oncol2001192153216411304767
   PubMed Web of Science ®Google Scholar
• HainsworthJDLitchySBartonJHSingle-agent rituximab as firstline and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase II trial of the Minnie Pearl Cancer Research NetworkJ Clin Oncol2003211746175112721250
   PubMed Web of Science ®Google Scholar
• ThomasDAO’BrienSGilesFJSingle agent rituximab in early stage chronic lymphocytic leukemiaBlood200198364a
   Google Scholar
• RaiKRPetersonBLAppelbaumFRFludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemiaN Engl J Med20003431750175711114313
   PubMed Web of Science ®Google Scholar
• PerzJTopalyJFruehaufSLevel of CD20 expression and efficacy of rituximab treatment in patients with resistant or relapsing B-cell prolymphocytic leukaemia and B-cell chronic lymphocytic leukaemiaLeuk Lymphoma20024314915111908720
   PubMed Web of Science ®Google Scholar
• ManshouriTCirculating CD20 is detectable in the plasma of patients with chronic lymphocytic leukemia and is of prognostic significanceBlood20031012507251312446458
   PubMed Web of Science ®Google Scholar
• MaloneyDGGrillo-LopezAJBodkinDJIDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin’s lymphomaJ Clin Oncol199715326632749336364
   PubMed Web of Science ®Google Scholar
• FurlanAVillanovaFPietrograndeFLow-dose fludarabine increases rituximab cytotoxicity in B-CLL cells by triggering caspases activation in vitroLeuk Lymphoma20105110711320001234
   PubMed Web of Science ®Google Scholar
• ChowKUSommerladWDBoehrerSAnti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement, and caspasesHaematologica200287334311801463
   PubMed Web of Science ®Google Scholar
• ByrdJCPetersonBLMorrisonVARandomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712)Blood200310161412393429
   PubMed Web of Science ®Google Scholar
• WoyachJARuppertASHeeremaNATreatment with fludarabine and rituximab produces extended overall survival (OS) and Progression-Free Survival (PFS) in chronic lymphocytic leukemia (CLL) without increased risk of second malignancy: long-term follow up of CALGB study 9712Blood2009114Abstract 539
   Web of Science ®Google Scholar
• ByrdJCRaiKPetersonBLAddition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011Blood2005105495315138165
   PubMed Web of Science ®Google Scholar
• SchulzHKleinSKRehwaldUPhase 2 study of a combined immunochemotherapy using rituximab and fludarabine in patients with chronic lymphocytic leukemiaBlood20021003115312012384407
   PubMed Web of Science ®Google Scholar
• HallekMSchmittBWilhelmMFludarabine plus cyclophosphamide is an efficient treatment for advanced chronic lymphocytic leukaemia (CLL): results of a phase II study of the German CLL Study GroupBr J Haematol200111434234811529853
   PubMed Web of Science ®Google Scholar
• FlinnIWByrdJCMorrisonCFludarabine and cyclophosphamide with filgrastim support in patients with previously untreated indolent lymphoid malignanciesBlood200096717510891432
   PubMed Web of Science ®Google Scholar
• O’BrienSMKantarjianHMCortesJResults of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemiaJ Clin Oncol2001191414142011230486
   PubMed Web of Science ®Google Scholar
• WierdaWO’BrienSWenSChemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemiaJ Clin Oncol2005234070407815767647
   PubMed Web of Science ®Google Scholar
• KeatingMJFlinnIJainVTherapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international studyBlood2002993554356111986207
   PubMed Web of Science ®Google Scholar
• RaiKRFreterCEMercierRJAlemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabineJ Clin Oncol2002203891389712228210
   PubMed Web of Science ®Google Scholar
• TsimberodouAMTamCAbruzzoLVChemoimmunotherapy may overcome the adverse prognostic significance of 11q deletion in previously untreated patients with chronic lymphocytic leukemiaCancer200911537338019117034
   PubMed Web of Science ®Google Scholar
• WierdaWO’BrienSFaderlSA retrospective comparison of three sequential groups of patients with Recurrent/Refractory chronic lymphocytic leukemia treated with fludarabine-based regimensCancer200610633734516353201
   PubMed Web of Science ®Google Scholar
• HallekMFingerle-RowsonGFinkAMImmunochemotherapy with fludarabine (F), cyclophosphamide (C), and rituximab (R) (FCR) versus fludarabine and cyclophosphamide (FC) improves response rates and progression-free survival (PFS) of previously untreated patients (pts) with advanced chronic lymphocytic leukemia (CLL)Blood2008112Abstract 325
   Web of Science ®Google Scholar
• LepretreSAurranTMaheBImmunochemotherapy with fludarabine (F), cyclophosphamide (C), and rituximab (R) (FCR) versus fludarabine (F), cyclophosphamide (C) and mabcampath (Cam) (FCCam) in previously untreated patients (pts) with advanced B-chronic lymphocytic leukemia (B-CLL): experience on safety and efficacy within a randomised multicenter phase III trial of the French Cooperative Group on CLL and WM (FCGCLL/MW) and the “Groupe Ouest-Est d’Etudes Des Leucémies Aigües Et Autres Maladies Du sang” (GOELAMS) :CLL2007FMP (for fit medically patients)Blood2009114 Abstract 538
   Web of Science ®Google Scholar
• FoonKABoyiadzisMLandSRChemoimmunotherapy with low-dose fludarabine and cyclophosphamide and high dose rituximab in previously untreated patients with chronic lymphocytic leukemiaJ Clin Oncol20092749850319075274
   PubMed Web of Science ®Google Scholar
• LamannaNJurcicJGNovASequential therapy with fludarabine, high-dose cyclophosphamide, and rituximab in previously untreated patients with chronic lymphocytic leukemia produces high-quality responses: molecular remissions predict for durable complete responsesJ Clin Oncol20092749149719075280
   PubMed Web of Science ®Google Scholar
• WeissMAMaslakPGJurcicJGPentostatin and cyclophosphamide: an effective new regimen in previously treated patients with chronic lymphocytic leukemiaJ Clin Oncol2003211278128412663715
   PubMed Web of Science ®Google Scholar
• LamannaNKalaycioMMaslakPPentostatin, cyclophosphamide, and rituximab is an active, well-tolerated regimen for patients with previously treated chronic lymphocytic leukemiaJ Clin Oncol2006241575158116520464
   PubMed Web of Science ®Google Scholar
• KayNEGeyerSMCallTGCombination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemiaBlood200710940541117008537
   PubMed Web of Science ®Google Scholar
• ShanafeltTDLinTGeyerSMPentostatin, cyclophosphamide, and rituximab regimen in older patients with chronic lymphocytic leukemiaCancer20071092291229817514743
   PubMed Web of Science ®Google Scholar
• ReynoldsCdi BellaNLyonsRMPhase III trial of fludarabine, cyclophosphamide, and rituximab vs pentostatin, cyclophosphamide, and rituximab in B-cell chronic lymphocytic leukemiaBlood2008112 Abstract 126
   Web of Science ®Google Scholar
• KayNEWuWKabatBPentostatin and rituximab therapy for previously untreated patients with B-cell chronic lymphocytic leukemiaCancer20101162180218720187101
   PubMed Web of Science ®Google Scholar
• RobakTSmolewskiPCebulaBRituximab plus cladribine with or without cyclophosphamide in patients with relapsed or refractory chronic lymphocytic leukemiaEur J Haematol20077910711317635235
   PubMed Web of Science ®Google Scholar
• BertazzoniPRabascioCGigliFRiruximab and subcutaneous cladribine in chronic lymphocytic leukemia for newly diagnosed and relapsed patientsLeuk Lymphoma2010511485149320578816
   PubMed Web of Science ®Google Scholar
• MontilloMRicciFTedeschiABendamustine: new perspective for an old drug in lymphoproliferative disordersExpert Rev Hematol2010313114821083456
   PubMed Web of Science ®Google Scholar
• FischerKStilgenbauerSSchweighoferCDBendamustine in combination with rituximab (BR) for patients with relapsed chronic lymphocytic Leukemia (CLL): a multicentre phase II trial of the German CLL Study Group (GCLLSG)Blood2008112 Abstract 330
   Web of Science ®Google Scholar
• FischerKCramerPStilgenbauerSBendamustine combined with rituximab (BR) in first-line therapy of advanced CLL: A multicenter phase II trial of the German CLL Study Group (GCLLSG)Blood2009114 Abstract 205
   Web of Science ®Google Scholar
• WeideRHessGKopplerHHigh anti-lymphoma activity of bendamustine/mitoxantrone/rituximab in rituximab pretreated relapsed or refractory indolent lymphomas and mantle cell lymphomas. A multicenter phase II study of the German Low Grade Lymphoma Study Group (GLSG)Leuk Lymphoma2007481299130617613757
   PubMed Web of Science ®Google Scholar
• HillmenPGribbenJGMDFollowsGAAn open-label phase II study to investigate the safety and efficacy of rituximab plus chlorambucil in previously untreated patients with CD20-positive B-cell chronic lymphocytic leukaemia (CLL)Blood2009114 Abstract 3428
   Web of Science ®Google Scholar
• BoschFFerrerAVillamorNFludarabine, cyclophosphamide, and mitoxantrone as initial therapy of chronic lymphocytic leukemia: high response rate and disease eradicationClin Cancer Res200814155156118172266
   PubMed Web of Science ®Google Scholar
• HendryLBowenAMatutesEFludarabine, cyclophosphamide and mitoxantrone in relapsed or refractory chronic lymphocytic leukemia and low grade non-Hodgkin’s lymphomaLeuk Lymphoma20044594595015291353
   PubMed Web of Science ®Google Scholar
• HillmenPPocockCCohenDNCRI CLL201 Trial: a randomized phase ii trial of fludarabine, cyclophosphamide and mitoxantrone (FCM) with or without rituximab in previously treated CLLBlood2007110 Abstract 752
   Web of Science ®Google Scholar
• BoschFAbrisquetaPVillamorNRituximab, fludarabine, cyclophosphamide, and mitoxantrone: a new, highly active chemoimmunotherapy regimen for chronic lymphocytic leukemiaJ Clin Oncol2009274578458419704063
   PubMed Web of Science ®Google Scholar
• FaderlSWierdaWO’BrienSFludarabine, cyclophosphamide, mitoxantrone plus rituximab (FCM-R) in frontline CLL < 70 yearsLeuk Res20103428428819646755
   PubMed Web of Science ®Google Scholar
• TsimberidouAMWierdaWPlunkettWPhase I-II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with Richter’s syndrome or fludarabine-refractory chronic lymphocytic leukemiaJ Clin Oncol200826219620318182662
   PubMed Web of Science ®Google Scholar
• TsimberidouAMO’BrienSMCortesJEPhase II study of fludarabine, cytarabine (Ara-C), cyclophosphamide, cisplatin and GM-CSF (FACPGM) in patients with Richter’s syndrome or refractory lymphoproliferative disordersLeuk Lymphoma20024376777212153163
   PubMed Web of Science ®Google Scholar
• GilesFJO’BrienSMSantiniVSequential cis-platinum and fludarabine with or without arabinosyl cytosine in patients failing prior fludarabine therapy for chronic lymphocytic leukemia: a phase II studyLeuk Lymphoma199936576510613450
   PubMed Web of Science ®Google Scholar
• TsimberidouAMWierdaWPlunkettWOxaliplatin, fludarabine, cytarabine, and rituximab combination therapy induces high response rates in agressive chronic lymphocytic Leukemia (CLL) and Richter’s syndrome (RS)Blood2009114 Abstract 3443
   Web of Science ®Google Scholar
• RossmannEDLundinJLenkeiRVariability in B-cell antigen expression: implications for the treatment of B-cell lymphomas and leukemias with monoclonal antibodiesHematol J2001230030611920265
   PubMedGoogle Scholar
• NabhanCPattonDGordonLIA pilot trial of rituximab and alemtuzumab combination therapy in patients with relapsed and/or refractory chronic lymphocytic leukemia (CLL)Leuk Lymphoma2004452269227315512816
   PubMed Web of Science ®Google Scholar
• FaderlSThomasDAO’BrienSExperience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignanciesBlood20031013413341512522009
   PubMed Web of Science ®Google Scholar
• FaderlSFerrajoliAWierdaWAlemtuzumab by continuous intravenous infusion followed by subcutaneous injection plus rituximab in the treatment of patients with chronic lymphocytic leukemia recurrenceCancer20101162360236520225334
   PubMed Web of Science ®Google Scholar
• FrankfurtOHamiltonEDuffeySAlemtuzumab and Rituximab Combination Therapy for Patients with Untreated CLL – a Phase II TrialBlood2008112 Abstract 2098
   Web of Science ®Google Scholar
• ZentCSCallTGShanafeltTDEarly treatment of high-risk chronic lymphocytic leukemia with alemtuzumab and rituximabCancer20081132110211818759253
   PubMed Web of Science ®Google Scholar
• WierdaWGO’BrienSFaderlSCombined cyclophosphamide, fludarabine, alemtuzumab, and rituximab (CFAR), an active regimen for heavily treated patients with CLLBlood2006108 Abstract 31
   Web of Science ®Google Scholar
• ParikhSAKeatingMO’BrienSFrontline Combined Chemoimmunotherapy with Fludarabine, Cyclophosphamide, Alemtuzumab and Rituximab (CFAR) in High-Risk Chronic Lymphocytic LeukemiaBlood2009114 Abstract 208
   Web of Science ®Google Scholar
• ByrdJCKippsTJFlinnIWPhase 1/2 study of lumiliximab combined with fludarabine, cyclophosphamide, and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemiaBlood201011548949519843887
   PubMed Web of Science ®Google Scholar
• ThorntonPDHamblinMTreleavenJGHigh dose methyl prednisolone in refractory chronic lymphocytic leukaemiaLeuk Lymphoma19993416717010350345
   PubMed Web of Science ®Google Scholar
• ThorntonPDMatutesEBosanquetAGHigh dose methylprednisolone can induce remissions in CLL patients with p53 abnormalitiesAnn Hematol20038275976514551737
   PubMed Web of Science ®Google Scholar
• CastroJESandoval-SusJDBoleJRituximab in combination with high-dose methylprednisolone for the treatment of fludarabine refractory high-risk chronic lymphocytic leukemiaLeukemia2008222048205318754025
   PubMed Web of Science ®Google Scholar
• QuinnJPMohamedbhaiSChipperfieldKEfficacy of rituximab in combination with steroids in refractory chronic lymphocytic leukemiaLeuk Lymphoma2008491995199818949622
   PubMed Web of Science ®Google Scholar
• BowenDACallTGJenkinsGDZentCSMethylprednisolone- rituximab is an effective salvage therapy for patients with relapsed chronic lymphocytic leukemia including those with unfavorable cytogenetic featuresLeuk Lymphoma2007482412241718067017
   PubMed Web of Science ®Google Scholar
• DungarwallaMEvansSORileyUHigh dose methylprednisolone and rituximab is an effective therapy in advanced refractory chronic lymphocytic leukemia resistant to fludarabine therapyHaematologica20089347547618310545
   PubMed Web of Science ®Google Scholar
• CastroJESandoval-SusJDJainSRituximab in combination with high-dose methylprednisolone for the treatment of chronic lymphocytic leukemiaLeukemia2009231779178919693094
   PubMed Web of Science ®Google Scholar
• VenugopalPSivaramanSHuangXKEffects of cytokines on CD20 antigen expression on tumor cells from patients with chronic lymphocytic leukemiaLeuk Res20002441141510785263
   PubMed Web of Science ®Google Scholar
• VosoMTPantelGRutellaSRituximab reduces the number of peripheral blood B-cells in vitro mainly by effector cell-mediated mechanismsHaematologica20028791892512217803
   PubMed Web of Science ®Google Scholar
• FerrajoliAIncorporating the use of GM-CSF in the treatment of chronic lymphocytic leukemiaLeuk Lymphoma20095051451619347738
   PubMed Web of Science ®Google Scholar
• FerrajoliAFaderlSO’BrienSExperience with fludarabine, cyclophosphamide, rituximab (FCR) plus GM-CSF in frontline therapy for chronic lymphocytic leukemia (CLL)Blood (ASH Annual Meeting Abstracts)2008112 Abstract 3173
   Google Scholar
• Chanan-KhanAMillerKCMusialLClinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II studyJ Clin Oncol2006245343534917088571
   PubMed Web of Science ®Google Scholar
• FerrajoliALeeBNSchletteEJLenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemiaBlood20081115291529718334676
   PubMed Web of Science ®Google Scholar
• WuLAdamsMCarterTLenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cellsClin Cancer Res2008144650465718628480
   PubMed Web of Science ®Google Scholar
• FerrajoliABadouxXCO’BrienSCombination Therapy with Lenalidomide and Rituximab in Patients with Relapsed Chronic Lymphocytic Leukemia (CLL)Blood2009114 Abstract 206
   Web of Science ®Google Scholar
• GhielminiMSchmitzSFCogliattiSBProlonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly × 4 scheduleBlood20041034416442314976046
   PubMed Web of Science ®Google Scholar
• SallesGASeymourJFFeugierPRituximab maintenance for 2 years in patients with untreated high tumor burden follicular lymphoma after response to immunochemotherapyJ Clin Oncol2010288004
   Web of Science ®Google Scholar
• van OersMHJKlasaRMarcusRERituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trialBlood20061083295330116873669
   PubMed Web of Science ®Google Scholar
• Del PoetaGDel PrincipeMIBuccisanoFConsolidation and maintenance immunotherapy with rituximab improve clinical outcome in patients with B-cell chronic lymphocytic leukemiaCancer200811211912817999417
   PubMed Web of Science ®Google Scholar
• Del PoetaGDel PrincipeMIRagusaDRituximab maintenance following chemoimmunotherapy improves outcome in B-cell chronic lymphocytic leukemiaBlood2009114 Abstract 2364
   Web of Science ®Google Scholar
• SrockSSchrieverFNeubauerALong-term treatment with rituximab is feasible in selected patients with B-CLL: response-adjusted low-dose maintenance treatment with rituximab in patients with relapsed B-CLL, who achieved a partial or minimal response to prior rituximab therapyLeuk Lymphoma20074890591117487734
   PubMed Web of Science ®Google Scholar
• AbrisquetaPPereiraARozmanCImproving survival in patients with chronic lymphocytic leukemia (1980–2008): the Hospital Clinic of Barcelona experienceBlood20091142044205019553638
   PubMed Web of Science ®Google Scholar
• BrennerHGonolonsAPulteDTrends in long-term survival of patients with chronic lymphocytic leukemia from the early 21st centuryBlood20081114916492118309034
   PubMed Web of Science ®Google Scholar